Imaging Biomarkers Market Size, Share & Trends Report by 2034

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Imaging Biomarkers Market Size Analysis

Global Imaging Biomarkers Market Introduction
By Type
1. Introduction
  1. Type By Value
2. Anatomical biomarkers
  1. By Value
3. Functional biomarkers
  1. By Value
4. Molecular/Nuclear Biomarkers
  1. By Value
5. Quantitative Imaging Biomarkers
  1. By Value
6. Others
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Positron Emission Tomography (PET)
  1. By Value
3. Ultrasound, Magnetic Resonance Imaging
  1. By Value
4. Computed Tomography (CT)
  1. By Value
5. Single-Photon Emission Computerized Tomography (SPECT)
  1. By Value
6. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Diagnostics
  1. By Value
3. Drug Discovery & Development
  1. By Value
4. Personalized Medicine
  1. By Value
5. Disease Risk Assessment
  1. By Value
6. Others
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals
  1. By Value
3. Diagnostic/imaging centers
  1. By Value
4. Pharmaceutical and Biotech Companies
  1. By Value
5. Others
  1. By Value

North America Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Anatomical biomarkers
  1. By Value
3. Functional biomarkers
  1. By Value
4. Molecular/Nuclear Biomarkers
  1. By Value
5. Quantitative Imaging Biomarkers
  1. By Value
6. Others
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Positron Emission Tomography (PET)
  1. By Value
3. Ultrasound, Magnetic Resonance Imaging
  1. By Value
4. Computed Tomography (CT)
  1. By Value
5. Single-Photon Emission Computerized Tomography (SPECT)
  1. By Value
6. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Diagnostics
  1. By Value
3. Drug Discovery & Development
  1. By Value
4. Personalized Medicine
  1. By Value
5. Disease Risk Assessment
  1. By Value
6. Others
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals
  1. By Value
3. Diagnostic/imaging centers
  1. By Value
4. Pharmaceutical and Biotech Companies
  1. By Value
5. Others
  1. By Value
U.S.
1. By Type
  1. Introduction
    1. Type By Value
  2. Anatomical biomarkers
    1. By Value
  3. Functional biomarkers
    1. By Value
  4. Molecular/Nuclear Biomarkers
    1. By Value
  5. Quantitative Imaging Biomarkers
    1. By Value
  6. Others
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. Positron Emission Tomography (PET)
    1. By Value
  3. Ultrasound, Magnetic Resonance Imaging
    1. By Value
  4. Computed Tomography (CT)
    1. By Value
  5. Single-Photon Emission Computerized Tomography (SPECT)
    1. By Value
  6. Others
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Diagnostics
    1. By Value
  3. Drug Discovery & Development
    1. By Value
  4. Personalized Medicine
    1. By Value
  5. Disease Risk Assessment
    1. By Value
  6. Others
    1. By Value
4. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals
    1. By Value
  3. Diagnostic/imaging centers
    1. By Value
  4. Pharmaceutical and Biotech Companies
    1. By Value
  5. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Anatomical biomarkers
  1. By Value
3. Functional biomarkers
  1. By Value
4. Molecular/Nuclear Biomarkers
  1. By Value
5. Quantitative Imaging Biomarkers
  1. By Value
6. Others
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Positron Emission Tomography (PET)
  1. By Value
3. Ultrasound, Magnetic Resonance Imaging
  1. By Value
4. Computed Tomography (CT)
  1. By Value
5. Single-Photon Emission Computerized Tomography (SPECT)
  1. By Value
6. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Diagnostics
  1. By Value
3. Drug Discovery & Development
  1. By Value
4. Personalized Medicine
  1. By Value
5. Disease Risk Assessment
  1. By Value
6. Others
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals
  1. By Value
3. Diagnostic/imaging centers
  1. By Value
4. Pharmaceutical and Biotech Companies
  1. By Value
5. Others
  1. By Value
U.K.
1. By Type
  1. Introduction
    1. Type By Value
  2. Anatomical biomarkers
    1. By Value
  3. Functional biomarkers
    1. By Value
  4. Molecular/Nuclear Biomarkers
    1. By Value
  5. Quantitative Imaging Biomarkers
    1. By Value
  6. Others
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. Positron Emission Tomography (PET)
    1. By Value
  3. Ultrasound, Magnetic Resonance Imaging
    1. By Value
  4. Computed Tomography (CT)
    1. By Value
  5. Single-Photon Emission Computerized Tomography (SPECT)
    1. By Value
  6. Others
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Diagnostics
    1. By Value
  3. Drug Discovery & Development
    1. By Value
  4. Personalized Medicine
    1. By Value
  5. Disease Risk Assessment
    1. By Value
  6. Others
    1. By Value
4. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals
    1. By Value
  3. Diagnostic/imaging centers
    1. By Value
  4. Pharmaceutical and Biotech Companies
    1. By Value
  5. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Anatomical biomarkers
  1. By Value
3. Functional biomarkers
  1. By Value
4. Molecular/Nuclear Biomarkers
  1. By Value
5. Quantitative Imaging Biomarkers
  1. By Value
6. Others
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Positron Emission Tomography (PET)
  1. By Value
3. Ultrasound, Magnetic Resonance Imaging
  1. By Value
4. Computed Tomography (CT)
  1. By Value
5. Single-Photon Emission Computerized Tomography (SPECT)
  1. By Value
6. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Diagnostics
  1. By Value
3. Drug Discovery & Development
  1. By Value
4. Personalized Medicine
  1. By Value
5. Disease Risk Assessment
  1. By Value
6. Others
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals
  1. By Value
3. Diagnostic/imaging centers
  1. By Value
4. Pharmaceutical and Biotech Companies
  1. By Value
5. Others
  1. By Value
China
1. By Type
  1. Introduction
    1. Type By Value
  2. Anatomical biomarkers
    1. By Value
  3. Functional biomarkers
    1. By Value
  4. Molecular/Nuclear Biomarkers
    1. By Value
  5. Quantitative Imaging Biomarkers
    1. By Value
  6. Others
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. Positron Emission Tomography (PET)
    1. By Value
  3. Ultrasound, Magnetic Resonance Imaging
    1. By Value
  4. Computed Tomography (CT)
    1. By Value
  5. Single-Photon Emission Computerized Tomography (SPECT)
    1. By Value
  6. Others
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Diagnostics
    1. By Value
  3. Drug Discovery & Development
    1. By Value
  4. Personalized Medicine
    1. By Value
  5. Disease Risk Assessment
    1. By Value
  6. Others
    1. By Value
4. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals
    1. By Value
  3. Diagnostic/imaging centers
    1. By Value
  4. Pharmaceutical and Biotech Companies
    1. By Value
  5. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Anatomical biomarkers
  1. By Value
3. Functional biomarkers
  1. By Value
4. Molecular/Nuclear Biomarkers
  1. By Value
5. Quantitative Imaging Biomarkers
  1. By Value
6. Others
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Positron Emission Tomography (PET)
  1. By Value
3. Ultrasound, Magnetic Resonance Imaging
  1. By Value
4. Computed Tomography (CT)
  1. By Value
5. Single-Photon Emission Computerized Tomography (SPECT)
  1. By Value
6. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Diagnostics
  1. By Value
3. Drug Discovery & Development
  1. By Value
4. Personalized Medicine
  1. By Value
5. Disease Risk Assessment
  1. By Value
6. Others
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals
  1. By Value
3. Diagnostic/imaging centers
  1. By Value
4. Pharmaceutical and Biotech Companies
  1. By Value
5. Others
  1. By Value
UAE
1. By Type
  1. Introduction
    1. Type By Value
  2. Anatomical biomarkers
    1. By Value
  3. Functional biomarkers
    1. By Value
  4. Molecular/Nuclear Biomarkers
    1. By Value
  5. Quantitative Imaging Biomarkers
    1. By Value
  6. Others
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. Positron Emission Tomography (PET)
    1. By Value
  3. Ultrasound, Magnetic Resonance Imaging
    1. By Value
  4. Computed Tomography (CT)
    1. By Value
  5. Single-Photon Emission Computerized Tomography (SPECT)
    1. By Value
  6. Others
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Diagnostics
    1. By Value
  3. Drug Discovery & Development
    1. By Value
  4. Personalized Medicine
    1. By Value
  5. Disease Risk Assessment
    1. By Value
  6. Others
    1. By Value
4. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals
    1. By Value
  3. Diagnostic/imaging centers
    1. By Value
  4. Pharmaceutical and Biotech Companies
    1. By Value
  5. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Type
1. Introduction
  1. Type By Value
2. Anatomical biomarkers
  1. By Value
3. Functional biomarkers
  1. By Value
4. Molecular/Nuclear Biomarkers
  1. By Value
5. Quantitative Imaging Biomarkers
  1. By Value
6. Others
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Positron Emission Tomography (PET)
  1. By Value
3. Ultrasound, Magnetic Resonance Imaging
  1. By Value
4. Computed Tomography (CT)
  1. By Value
5. Single-Photon Emission Computerized Tomography (SPECT)
  1. By Value
6. Others
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Diagnostics
  1. By Value
3. Drug Discovery & Development
  1. By Value
4. Personalized Medicine
  1. By Value
5. Disease Risk Assessment
  1. By Value
6. Others
  1. By Value
By End User
1. Introduction
  1. End User By Value
2. Hospitals
  1. By Value
3. Diagnostic/imaging centers
  1. By Value
4. Pharmaceutical and Biotech Companies
  1. By Value
5. Others
  1. By Value
Brazil
1. By Type
  1. Introduction
    1. Type By Value
  2. Anatomical biomarkers
    1. By Value
  3. Functional biomarkers
    1. By Value
  4. Molecular/Nuclear Biomarkers
    1. By Value
  5. Quantitative Imaging Biomarkers
    1. By Value
  6. Others
    1. By Value
2. By Technology
  1. Introduction
    1. Technology By Value
  2. Positron Emission Tomography (PET)
    1. By Value
  3. Ultrasound, Magnetic Resonance Imaging
    1. By Value
  4. Computed Tomography (CT)
    1. By Value
  5. Single-Photon Emission Computerized Tomography (SPECT)
    1. By Value
  6. Others
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Diagnostics
    1. By Value
  3. Drug Discovery & Development
    1. By Value
  4. Personalized Medicine
    1. By Value
  5. Disease Risk Assessment
    1. By Value
  6. Others
    1. By Value
4. By End User
  1. Introduction
    1. End User By Value
  2. Hospitals
    1. By Value
  3. Diagnostic/imaging centers
    1. By Value
  4. Pharmaceutical and Biotech Companies
    1. By Value
  5. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Imaging Biomarkers Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Alamar Biosciences, Inc.
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
IXICO plc
Quibim
Siemens Healthineers AG
GE HealthCare
Koninklijke Philips NV
CANON MEDICAL SYSTEMS CORPORATION
FUJIFILM Holdings Corporation
Bruker
AGFA HealthCare
Hologic, Inc.
Revvity Inc.
Clario
Merck KGaA
Thermo Fisher Scientific Inc.
Median Technologies
Bio-Rad Laboratories, Inc.
Abcam Limited
QIAGEN
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Shimadzu Corporation
Konica Minolta, Inc.
Others

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment